Business context and reporting period
This is Oncobiologics, Inc.’s unaudited Form 10-Q for the fiscal quarter and six months ended March 31, 2016. The request identifies Outlook Therapeutics, but the filing names Oncobiologics as the registrant; verify the company and filing match your intended review. Oncobiologics was a clinical-stage biosimilar developer with no approved products or product-sale revenue. Its lead candidates were ONS-3010 (adalimumab/Humira) and ONS-1045 (bevacizumab/Avastin); each had completed Phase 1, and ONS-3010 was being prepared for Phase 3.
Financial performance and position
| Metric | Three months ended Mar. 31, 2016 | Six months ended Mar. 31, 2016 | Comparable 2015 period |
|---|---|---|---|
| Collaboration revenue | $1.0 million | $2.0 million | $0.5 million; $3.4 million |
| Operating loss | $3.0 million | $19.4 million | $14.0 million; $18.1 million |
| Net loss | $3.5 million | $20.4 million | $14.0 million; $18.9 million |
| Net loss attributable to common stockholders | $4.6 million | $22.4 million | $15.1 million; $22.3 million |
| Net loss per share, basic and diluted | $(0.32) | $(1.64) | $(1.61); $(2.38) |
- Six-month R&D expense was $16.9 million, up from $16.0 million; G&A was $4.5 million, down from $5.6 million. No operating or profit margin was reported.
- Six-month operating cash outflow was $19.1 million, compared with $6.4 million in 2015. Investing outflow was $0.3 million; financing provided $13.2 million. Cash fell $6.2 million to $2.8 million.
- At March 31, current assets were $4.1 million and current liabilities $36.0 million, a working-capital deficit of approximately $31.9 million. Total liabilities were $45.3 million; accumulated deficit was $114.5 million.
- Debt and capital-lease obligations totaled approximately $14.7 million, including $9.7 million of current stockholder notes. The notes were described as payable on demand. The filing’s liquidity discussion also cites $8.9 million of indebtedness due on demand, an inconsistency to verify.
Changes, outlook, risks and unusual items
- Six-month revenue fell $1.4 million year over year, mainly because milestone payments decreased by $1.5 million. Second-quarter revenue rose $0.5 million year over year from a milestone payment.
- Six-month net loss increased $1.5 million despite lower G&A and interest expense. R&D investment rose in personnel and ONS-3010 clinical and regulatory work.
- Reported expenses were materially affected by stock-based compensation accounting: the second-quarter G&A line was a $189,438 credit, and six-month stock-based compensation was reported as income of $2.0 million. The filing attributes changes in part to PSU remeasurement and reclassification; these should not be read as recurring operating savings.
- Management stated that May 2016 IPO and concurrent private-placement proceeds totaled approximately $34.4 million net and were expected to fund operations through June 2017. The filing nevertheless says substantial additional financing will be needed and that continued losses raise substantial doubt about the company’s ability to continue as a going concern.
- Subsequent events: the May offering followed a 1-for-3.45 reverse stock split; the filing says share and per-share data were retrospectively adjusted. Series A preferred stock converted into common stock at the IPO. Warrants may create additional dilution.
- Management planned to start ONS-3010 Phase 3 in 2016. ONS-1045 Phase 3 was contingent on additional funding. Trial results, regulatory requirements, financing availability, competition and commercialization remain significant uncertainties.
- Huahai’s ONS-3010 rights in major markets involve shared development costs and value ownership. The filing states Huahai must pay Oncobiologics $9.1 million to maintain 51% ownership; the status and conditions of this payment are important to confirm.
- The filing reports no material pending legal actions and no material change to previously disclosed risk factors. It also marks “No” to the question of whether all required Exchange Act reports had been filed during the preceding 12 months; verify the filing-status disclosure.
Key facts investors should verify
- That Oncobiologics, rather than Outlook Therapeutics, is the intended issuer and filing.
- Cash runway assumptions after the IPO, expected spending, and the timing and amount of additional financing needed.
- The amount and demand status of stockholder notes, and the filing’s differing disclosures of demand debt.
- Huahai’s $9.1 million payment obligation, ONS-3010 ownership and cost-sharing terms, and any resulting development or commercialization rights.
- Phase 3 start dates, required funding, regulatory plans and milestone conditions for both lead candidates; also assess potential warrant and equity dilution.